“Medical oncologists, including academic and in the community, tend to order more genomic testing than urologic oncologists,” says Dalia Kaakour, MD, MS, MPH.
In this video, Dalia Kaakour, MD, MS, MPH, highlights the study, “Real-world genomic testing patterns in patients with prostate cancer,” which was presented at the 2024 ASCO Genitourinary Cancers Symposium in San Francisco, California. Kaakour is a hematology and oncology fellow at the University of California, Irvine.
This specific project comes from a larger project where we created a survey that's been distributed to different providers, including medical oncologist, urologic oncologists, and radiation oncologists, as well as advanced care providers that work in those settings in order to examine disparities in prostate cancer care, including things such as initial biopsy, treatment, genomic testing, and beyond. This is a part of that larger project, looking specifically at genomic testing patterns, both between different provider groups and also between the academic and community setting.
Our study is ongoing, we only have about 47 responses so far. So, we really are inviting all providers that would fit into any of those categories to be involved in our survey. From the limited information we have so far, just generally speaking, we've seen that in the academic compared to the community setting, providers are initiating genomic testing earlier on compared to their community counterparts. Medical oncologists, including academic and in the community, tend to order more genomic testing than urologic oncologists.
This transcription has been edited for clarity.